What studies of melatonin found
At a glance, by condition
ME/CFS: C Mixed results
Based on the strongest evidence, randomised trials (very low certainty), for overall symptoms.
3 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies of melatonin for ME/CFS disagree, so it’s not clear whether it helps. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Melatonin · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Fatigue1 study · 58 people took melatonin Uncertain –
Why this grade: Uncertain, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (58 in all); helped less than agomelatine group (group a), an active treatment; not a sign of harm.
The randomised trial62 randomised · 58 analysed · 12 weeks (phase I) and 24 weeks from enrollment (phase II) · 10 mg/die
Fatigue improved less than with the comparison treatment.
Melatonin helped fatigue less than agomelatine group (group a) in the one comparison. Uncertain · low certainty –
- Some concerns about bias (RoB 2)
- Few people (58 in all)
- Helped less than agomelatine group (group a), an active treatment; not a sign of harm
Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed
Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): perception of physical fatigue (physical functioning domain), better.
Shown, not counted: melatonin was given together with other treatments.
See the 1 study
-
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. (2014)
- People in the study
- 62 randomised · 58 analysed
- Dose
- 10 mg/die
- Outcome
- FSS Krupp Fatigue Severity Scale
- Effect
- worse (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Daily life and health overall
Overall symptoms2 studies · 88 people took melatonin Mixed results C
Why this grade: Mixed results, very low certainty, from randomised trials: some concerns about bias (RoB 2); few people (88 in all); the studies disagree; randomised trials found mixed results.
Randomised trials2 studies · 88 people with results
Studies disagree about overall symptoms.
Studies disagree about whether melatonin helps overall symptoms. Mixed results · very low certainty C
- Some concerns about bias (RoB 2)
- Few people (88 in all)
- The studies disagree
See the 2 studies
-
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. (2014)
- People in the study
- 62 randomised · 58 analysed
- Dose
- 10 mg/die
- Outcome
- CGI Clinical Global Impression Severity
- Effect
- worse (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 42 randomised · 30 analysed
- Dose
- 5 mg capsules, each evening for 12 weeks, 2·5 h before the median time of going to bed during the preceding 4 weeks
- Outcome
- principal symptoms of CFS and general measures of physical or mental health
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- High
Quality of life1 study · 58 people took melatonin Uncertain –
Why this grade: Uncertain, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (58 in all); helped less than agomelatine group (group a), an active treatment; not a sign of harm.
The randomised trial62 randomised · 58 analysed · 12 weeks (phase I) and 24 weeks from enrollment (phase II) · 10 mg/die
Quality of life improved less than with the comparison treatment.
Melatonin helped quality of life less than agomelatine group (group a) in the one comparison. Uncertain · low certainty –
- Some concerns about bias (RoB 2)
- Few people (58 in all)
- Helped less than agomelatine group (group a), an active treatment; not a sign of harm
Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed
Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): mental component summary, no clear difference.
Shown, not counted: melatonin was given together with other treatments.
See the 1 study
-
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. (2014)
- People in the study
- 62 randomised · 58 analysed
- Dose
- 10 mg/die
- Outcome
- SF-12 SF-12 health survey
- Effect
- worse (not tested)
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Studies of combinations
Outcomes that only studies of melatonin given together with other treatments looked at. Shown, not graded: they can’t tell what melatonin did alone.
Smell and taste loss Both together
Combination: Melatonin + Multivitamins (Centrum) + Sodium citrate nasal spray66 in the study
Investigating the efficacy of melatonin, topical sodium citrate, and multivitamin with zinc as a potential treatment for postinfectious loss of smell. (2024): improvement in olfactory loss categories (anosmia, microsmia, or normosmia), no clear difference.
Shown, not counted: melatonin was given together with other treatments.
Cognition (brain fog) ME/CFS
Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed
Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): cognitive domain, no clear difference.
Shown, not counted: melatonin was given together with other treatments.
Daily functioning ME/CFS
Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed
Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): psychological domain, no clear difference.
Shown, not counted: melatonin was given together with other treatments.
Pain ME/CFS
Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed
Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): bodily pain, no clear difference.
Shown, not counted: melatonin was given together with other treatments.
Low mood or anxiety ME/CFS
Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed
Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): emotional role functioning, no clear difference.
Shown, not counted: melatonin was given together with other treatments.
Sleep ME/CFS
Combination: Melatonin + Zinc72 randomised · 60 started · 50 analysed
Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021): any component of the self-administered scale, no clear difference.
Shown, not counted: melatonin was given together with other treatments.
Sleep Long COVID
Combination: Methylphenidate (Ritalin, Concerta) + Sodium oxybate (Xyrem, Xywav) + Melatonin + Gabapentin (Neurontin)1 in the study
1171 Hypersomnia Secondary to Long Covid (2024): sleep inertia, better (not tested).
Shown, not counted: melatonin was given together with other treatments.
Daily functioning Long COVID
Combination: Methylphenidate (Ritalin, Concerta) + Sodium oxybate (Xyrem, Xywav) + Melatonin + Gabapentin (Neurontin)1 in the study
1171 Hypersomnia Secondary to Long Covid (2024): return to school full time and reached normal functioning, better (not tested).
Shown, not counted: melatonin was given together with other treatments.
Side effects
Stopping because of side effects1 study
Both treatments were well tolerated and not considered responsible for study withdrawals
Therapy of circadian rhythm disorders in chronic fatigue syndrome: no symptomatic improvement with melatonin or phototherapy. (2002)
Side effects studies reported1 kind
| Side effect | Studies that reported it |
|---|---|
| Fatigue | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
2 to 5 mg at the start in most studies
- 2Top dose
Most often 5 mg (3 of 8 studies)
Doses across 8 studies
1 to 5 mg. One study of 58 people went up to 10 mg.
Each study’s dose, as printed
- 10 mg/die Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. (2014)
- 4 mg daily, late afternoon Amplified amplitudes of circadian rhythms and nighttime hypotension in patients with chronic fatigue syndrome: improvement by inopamil but not by melatonin. (1998)
- 5 mg, to be taken at night Investigating the efficacy of melatonin, topical sodium citrate, and multivitamin with zinc as a potential treatment for postinfectious loss of smell. (2024)
- 2 mg retardiert, abendlich 30 min vor dem Zubettgehen [Sleep disorders and fatigue syndrome in long COVID syndrome: case-based experiences from neurological/sleep medicine rehabilitation]. (2022)
- 1 mg, once daily at night (30 min before bedtime) for 16 weeks Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. (2021)
- 5 mg capsules, each evening for 12 weeks, 2·5 h before the median time of going to bed during the preceding 4 weeks Therapy of circadian rhythm disorders in chronic fatigue syndrome: no symptomatic improvement with melatonin or phototherapy. (2002)
- 5 mg, 5 h before DLMO during 3 months Influence of melatonin on fatigue severity in patients with chronic fatigue syndrome and late melatonin secretion. (2006)
- 2 mg Ocular and Neurological Sequelae in Long COVID: Dry Eye, Asthenopia, Sleep Disorders, Asthenia, and Restless Legs Syndrome-A Case Report with Literature Review. (2025)
All papers
- Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study.2014 · randomised trial · 62 randomised · 58 analysed
Summary
This longitudinal proof-of-concept study asked whether agomelatine affects fatigue in people with Chronic Fatigue Syndrome (CFS) and compared it with melatonin to separate melatonin-receptor agonism from 5HT2C antagonism. Sixty-two subjects with CFS were recruited through clinician referrals and self-referrals and randomized to agomelatine 50 mg/die or sustained release melatonin 10 mg/die for 12 weeks (phase I). At week 12, melatonin-treated subjects were switched to agomelatine and re-evaluated after 12 more weeks, i.e. after 24 weeks from enrollment (phase II). Evaluations used the Krupp Fatigue Severity Scale (FSS), Clinical Global Impression Severity (CGI-S), SF-12, Hospital Anxiety and Depression Scale (HADS), Epworth Sleepiness Scale (ESS) and the Frequency, Intensity, and Burden of Side Effects Rating Scale (FIBSER). Four subjects out of 62 were not available at week 12 and discontinued during phase one (three in the melatonin group and one in the agomelatine group); full data were available for the remaining 58 subjects. The paper reports a significant reduction of perceived fatigue on FSS and CGI and an increase in perceived quality of life on SF-12 with agomelatine but not with melatonin. The switch from melatonin to agomelatine was associated with reduced fatigue levels and increased perceived quality of life. There were no statistically significant differences in side-effect perception between groups at the end of phase I, and the switch was not associated with a significant change in FIBSER scores; agomelatine was well tolerated by all enrolled subjects.
- Therapy of circadian rhythm disorders in chronic fatigue syndrome: no symptomatic improvement with melatonin or phototherapy.2002 · randomised trial · 42 randomised · 30 analysed
Summary
This randomized crossover study enrolled 42 subjects with chronic fatigue syndrome diagnosed by the Oxford criteria, identified through hospital clinics and patient groups in north-west England; 30 completed both treatment phases. Each patient was studied for 60 weeks, beginning with 12 weeks of placebo capsules, then received melatonin (5 mg capsules orally each evening for 12 weeks, 2·5 h before the median bedtime) and phototherapy (2500 Lux for 1 h each morning for 12 weeks) in random order, separated by a 12-week washout. Symptoms were measured with visual analogue scales, the Shortform (SF-36) Health Survey, Mental Fatigue Inventory and Hospital Anxiety and Depression Scale; body temperature rhythm and timing of melatonin secretion were also assessed. Neither intervention showed any significant effect on the principal symptoms or on general measures of physical or mental health. With phototherapy, sleep disturbance showed a marginal improvement (P = 0·03) and temperature phase advanced by 0·8 h (P = 0·04). With melatonin, isolated SF-36 changes were worsening of bodily pain (P = 0·044), increased vitality (P = 0·016) and improved mental health (P = 0·046), all falling short of the predetermined threshold. MFI and HAD showed no significant treatment effects. Both treatments were well tolerated and not considered responsible for study withdrawals; thirty of the 42 subjects completed both treatment phases.
- Amplified amplitudes of circadian rhythms and nighttime hypotension in patients with chronic fatigue syndrome: improvement by inopamil but not by melatonin.1998 · compared with another group · 18 in the study · 17 with outcome data
Summary
This open-label pilot study examined circadian cardiovascular rhythms in chronic fatigue syndrome (CFS) and then tested melatonin and inopamil in four patients from the study population. Ambulatory blood pressure was measured in 18 patients fulfilling 1987 CDC criteria for CFS and in 12 age-matched normotensive controls. One patient was hypertensive and was excluded; data from the remaining 17 patients (15 women, 2 men) were analysed. Patients showed a significant 12-hour heart-rate rhythm and 24-hour systolic and diastolic blood pressure rhythms. Although synchronous with control rhythms, patient amplitudes were 2.8, 2.8, and 9.0 times the control group rhythms (p < 0.001, p < 0.001, and p < 0.0001). Nighttime systolic blood pressure was consistently below 100 mm Hg. In the four-patient pilot, melatonin 4 mg daily in the late afternoon for the first 4-week period increased nighttime hypotension (p < 0.02), and inopamil 200 mg daily for the second 4-week period reduced it (p < 0.05); fatigue symptoms deteriorated during melatonin and improved during inopamil. Patients were tested after 4 and after 8 weeks. The authors state their material is small, and causality cannot be derived.
- Patient-reported treatment outcomes in ME/CFS and long COVID.2025 · no comparison group · 5,451 in the study · 3,925 with outcome data
- Influence of melatonin on fatigue severity in patients with chronic fatigue syndrome and late melatonin secretion.2006 · no comparison group · 29 in the study
Summary
This open label study enrolled 29 patients with chronic fatigue syndrome (CFS), 24 women and five men, seen at the specialist CFS outpatient clinic of the Gelderse Vallei hospital. Patients had dim light melatonin onset (DLMO) later than 21.30 hours. They took melatonin 5 mg orally 5 hours before DLMO for 3 months. There was no separate comparison group; checklist individual strength (CIS) scores after treatment were compared with scores from a pre-treatment period. CIS total score and the sub-scores for fatigue, concentration, motivation and activity improved significantly during treatment. The fatigue sub-score normalized in two of 29 patients before treatment and in eight of 27 patients during treatment; this change was significant (P = 0,031). In patients with DLMO later than 22.00 hours (n = 21), total CIS score and the sub-scores for fatigue, concentration and activity improved significantly more than in patients (n = 8) with DLMO earlier than 22.00 hours; motivation did not differ significantly. There were no dropouts, and side effects were not reported. The authors state that the results cannot be used to justify treatment with melatonin in CFS patients and that a randomized placebo-controlled study is needed.
- HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multiple Sclerosis Responsive to Rituximab.2025 · case report
Summary
This case report describes a single male patient in his 30s with a co-diagnosis of ME/CFS and MS, followed longitudinally. After a new MS relapse with radiological inflammation, he received rituximab at 1 g on days 1 and 15 of the first month, then nine monthly doses of 1 g adjusted by B-cell repopulation, a 9-month treatment regime. There was no comparison group; outcomes were before-versus-after observations in this patient. The report states a significant improvement in fatigue after the third dose, enabling increased mobility and participation in daily activities such as walking and dining out. On the Bell scale for severity assessment, the patient changed from a level of 10 to 20. After treatment he could leave the house 2–3 times a week and take gentle walks for an hour, and he reported a migraine once a month. The authors report he stayed in remission for at least 3 years after treatment. Harms of rituximab were not reported. The authors note limitations including sub-optimal frequency of MRI to monitor lesion progression and of HERV reassessment after rituximab, and the limited external validity of single study cases.
- Ocular and Neurological Sequelae in Long COVID: Dry Eye, Asthenopia, Sleep Disorders, Asthenia, and Restless Legs Syndrome-A Case Report with Literature Review.2025 · combination: given with other treatments · 1 in the study
Summary
This case report describes one 59-year-old Caucasian male with long COVID who was evaluated in an ophthalmology clinic for about six weeks of ocular burning, foreign body sensation, and asthenopia, plus asthenia, sleep disturbance, and restless legs syndrome. He received a tear substitute four times a day in both eyes, an antibiotic ointment before bedtime, oral Colinplus Delta®, zinc gluconate 17.4 mg and selenium methionine 100 mcg in the evening, and melatonin 2 mg orally, for six weeks. There was no comparison group; outcomes were compared with before treatment. At 6 weeks the patient reported significant improvement in ocular symptoms and resolution of irritative disorders and asthenopia, with complete resumption of work and daily activities. OSDI was 36 at baseline and 11 at 6 weeks; TBUT was 3 s right and 2 s left at baseline and 9 s right and 8 s left at 6 weeks; Schirmer I was 8 mm right and 6 mm left at baseline and 10 mm right and 9 mm left at 6 weeks. Reading speed improved from 95 to 222 wpm, and PPC from 38 cm to 19 cm. A reduction in asthenia, insomnia, and RLS was reported. Harms and withdrawals were not reported.
- Investigating the efficacy of melatonin, topical sodium citrate, and multivitamin with zinc as a potential treatment for postinfectious loss of smell.2024 · combination: given with other treatments · 66 in the study
Summary
Investigators retrospectively analysed medical records of 66 patients with olfactory loss after upper airway infection, including COVID-19, at a Smell and Taste Clinic. They compared 33 patients who received olfactory training alone with 33 who received olfactory training plus melatonin, sodium citrate, and multivitamins with zinc (Centrum®). Olfactory training was sniffing four odors twice a day for 10 s over 3 months. The treatment group was prescribed 5 mg melatonin at night, one Centrum® tablet every 12 h, and one jet of 9% sodium citrate to each nostril one hour before lunch and dinner for 90 days. Olfactory function was assessed with UPSIT® scores and self-reported outcomes after 3 months of therapy. There was no significant difference in the proportion who improved on UPSIT scores between groups (OR = 1.43, 95% CI 0.43–4.8, p = 0.56). In the olfactory training alone group, 21.2% (n = 7) showed improvement; in the medications group, 24.2% (n = 8) showed improvement. There was also no significant difference in improvement in olfactory loss categories (p = 0.84). Self-reported olfactory ability improvement was 64% in both groups (p = 1), and a decrease in discomfort was reported by 33% of controls and 36% of the treated group (p = 1). Among reported adverse effects, 5 patients (15%) reported nasal burning following the use of sodium citrate. The paper does not report withdrawals for harms. The authors state limitations including the retrospective design, lack of randomization, and small sample size.
- 1171 Hypersomnia Secondary to Long Covid2024 · combination: given with other treatments · 1 in the study
- [Sleep disorders and fatigue syndrome in long COVID syndrome: case-based experiences from neurological/sleep medicine rehabilitation].2022 · combination: given with other treatments · 4 in the study
Summary
Four case examples from a neurological/sleep medicine rehabilitation clinic described adults after COVID-19 with Long-COVID/Post-COVID symptoms. The report included one 30-year-old woman, one 48-year-old woman, one 18-year-old and one 31-year-old; no comparison group and no randomisation were reported. Treatments were multimodal and individual: movement/sport/physiotherapy and slowly built circuit training in Fall 1 over seven weeks, plus melatonin 2 mg retardiert in the evening; neuropsychological therapy, sport therapy with circuit training, light walking and increasing walking distance in Fall 2 over eight weeks, plus regular melatonin 2 mg retardiert; sport, physiotherapy, ergotherapy and low-dose Mestinon plus antidepressants in Fall 3 over ten weeks; physiotherapy, ergotherapy, speech therapy, lamotrigine 50 mg and valproic acid 300 mg 3× daily in Fall 4 during a twelve-week stay. Reported outcomes included physical performance, heart rate, sleep fragmentation, sleep quality, neuropsychological tests, subjective performance, hypersensitivity and sleep-onset insomnia. Fall 1 reported improvement over seven weeks, heart rate reduction to 64/min and 80% improvement of baseline symptoms; sleep fragmentation reduced after three weeks of melatonin and sleep quality was satisfactory after six weeks. Fall 2 reported increased physical performance within eight weeks, return to 70% of baseline performance, and improved insomnia with melatonin. Fall 3 reported no substantial clinical improvement after ten weeks. Fall 4 reported improved hypersensitivity within ten weeks and complete resolution of sleep-onset insomnia within the twelve-week stay. Harms and withdrawals were not reported.
- Effect of Melatonin Plus Zinc Supplementation on Fatigue Perception in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.2021 · combination: given with other treatments · 72 randomised · 60 started · 50 analysed
Summary
This 16-week randomized, double-blind, placebo-controlled trial asked whether oral melatonin plus zinc changes fatigue perception in ME/CFS. Participants were women with ME/CFS confirmed by the 1994 CDC/Fukuda case definition, recruited from a single outpatient tertiary referral center in Barcelona. The paper reports 72 randomized, 60 visited at baseline, and 50 completing the final assessment at 20 weeks. The melatonin plus zinc group received 1 mg melatonin plus 10 mg zinc once daily at night for 16 weeks; the comparison group received matching placebo. Outcomes were assessed at baseline, after 8 and 16 weeks of treatment, and 4 weeks post-treatment. Measures included FIS-40 fatigue, SF-36 quality of life, PSQI sleep, HADS anxiety/depression, and urinary 6-sulphatoxymelatonin and serum zinc. The results text reports physical fatigue perception improved at 16 weeks versus placebo (p = 0.026) and versus baseline (p = 0.012) in the melatonin plus zinc group. The SF-36 physical component summary improved at 8 and 16 weeks (p = 0.02 and p = 0.032). The paper reports no between-group differences for FIS-40 total score, SF-36 mental component summary, PSQI components, or HADS domains. It reports worsening after treatment withdrawal in physical functioning (p = 0.011), mental health status (p = 0.003), and sleep latency (p = 0.041). Seven participants (12%) abandoned the study; three (5%) were lost to follow-up. No relevant treatment-related adverse events were recorded. The authors state limitations: a small sample of 50 women, single-center recruitment, pre-established timing and doses, and no control for confounders.
- Nutraceutical Supplementation Effects on Subjective Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review.2025 · systematic review
Summary
Review authors searched ClinicalTrials.gov, Medline, PubMed, Cochrane and Web of Science for interventional studies of nutraceuticals or diet in adults with ME/CFS and included 14 studies, described as randomised controlled trials and open-label pilot trials. Interventions included CoQ10 (alone or with alpha-lipoic acid, NADH or selenium), NADH, melatonin with zinc, anhydrous enol-oxaloacetate, sodium dichloroacetate, hydrogen water, Ginkgo with Cistanche, guanidinoacetic acid, 6-methylsulfinylhexyl isothiocyanate, D-ribose, porcine serum polypeptide and probiotics, given for varying durations, with fatigue measured by self-report scales. CoQ10 plus alpha-lipoic acid lowered FSS scores (p < 0.0001); CoQ10 plus NADH lowered FIS-40 (p = 0.03; p < 0.001) and maximum HR (p = 0.022), with pain and sleep not significant; CoQ10 plus selenium lowered FIS-40 (p = 0.021); melatonin with zinc lowered FIS-40 (p < 0.05) without improving sleep or anxiety; probiotics improved the mental component (p = 0.043). Fatigue was not significant with guanidinoacetic acid, or with 6-MSITC on the CFQ-11. Reported side effects included dyspepsia (2/23 at 500 mg BID and 2/24 at 1,000 mg BID) and insomnia (1/26) with enol-oxaloacetate, epigastralgia and dizziness, tremor in one patient, and symptom flare-up in one patient. A meta-analysis was not conducted.
- Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.2015 · systematic review
Summary
This systematic review examined treatments for adults with ME/CFS. It included 35 treatment trials in 45 publications; trials enrolled predominantly middle-aged women from ME/CFS specialty clinics and used CFS case definitions. Treatments were compared with placebo, usual care, wait-list, relaxation, adaptive pacing, CBT, or other therapies. In 2 fair-quality trials (n=324), rintatolimod improved cardiopulmonary exercise test tolerance (36.5% versus 15.2%; P=0.047), exercise duration (10.3% versus 2.1%; P=0.007), and exercise work (11.8% versus 5.8%; P=0.01). In a small trial of 30 participants, valganciclovir improved fatigue on 1 scale but showed no statistically significant differences for other measures. Trials of galantamine, hydrocortisone, IgG, isoprinosine, and fluoxetine indicated no beneficial effects but were limited by small numbers. Counseling and behavior therapies improved fatigue, function, quality of life, work impairment, and global improvement in some trials (low to moderate strength of evidence). A meta-analysis of 4 CBT trials found no statistically significant difference in SF-36 physical function (weighted mean difference, 10.42 [95% Cl, -3.86 to 24.69]); a sensitivity analysis found 6.02 [Cl, 1.05 to 10.88]. GET improved function (10.68 [Cl, 6.32 to 16.88]), fatigue (4 trials, n=619), and global improvement (relative risk, 1.58 [Cl, 1.24 to 2.47]). In the PACE trial, deterioration of physical function was 25% with adaptive pacing, 18% with usual care, and 11% with GET (P<0.001). Harms included galantamine: 90% reported harms and 2% serious events, none attributed to study drug; IgG headaches 93% versus 60%; GET serious adverse events 17 versus 7. GET withdrawals were 37% versus 22%, and 20% declined repeat exercise testing. Adverse effects were rarely reported overall.
- Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review.2011 · systematic review
Summary
This systematic review examined randomised controlled trials of complementary and alternative medicine (CAM) for patients with chronic fatigue syndrome (CFS), also termed myalgic encephalomyelitis (ME). The search was up to 13th August 2011. A total of 26 RCTs, which included 3,273 participants, met the inclusion criteria. The CAM therapies included mind-body medicine, distant healing, massage, tuina and tai chi, homeopathy, ginseng, and dietary supplementation. The review reports that studies of qigong, massage and tuina demonstrated positive effects, whereas distant healing failed to show a significant effect on mental or physical components of quality of life. Compared with placebo, homeopathy had insufficient evidence of symptom improvement in CFS. Most supplements failed to show beneficial effects for CFS, with the exception of NADH and magnesium. Five of the 26 included studies reported no adverse events or a slight occurrence of them, and the other included studies lacked descriptions regarding adverse events; no severe adverse effects of CAM were noted. The authors state that firm conclusions are difficult with the limited number of RCTs for each therapy, small sample sizes and high risk of bias.
- Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
Summary
This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.
- The potential therapeutic approaches targeting gut health in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a narrative review.2025 · review
Summary
This narrative review searched English peer-reviewed literature from January 1995 to January 2025 via PubMed, Scopus, and Web of Science to synthesize data on gut microbiota, inflammatory markers, and therapeutic outcomes in ME/CFS. The review did not report enrolling patients. It describes probiotic studies: an Italian pilot 8-week course improved well-being and reduced inflammation; in 15 ME/CFS patients, three strains improved neurocognitive function but no significant fatigue or physical activity reduction in only nine patients; Bifidobacterium infantis 35,624 in 48 patients lowered CRP, TNF-α, and IL-6. A 12-week Ubiquinol-10 randomized trial reported no significant fatigue improvement but reduced night-time awakenings; a 16-week randomized placebo-controlled trial of oral melatonin (1 mg) and zinc (10 mg) in 50 patients showed reductions in physical fatigue and improved quality of life. FMT: a retrospective study of 60 patients reported 70% response after four weeks and 58% maintained resolution for 15–20 years; another reported 17 of 21 patients with at least 60% improvement; a randomized placebo-controlled pilot in 11 patients (5 universal donor, 6 autologous) found no notable quality-of-life differences at 1 and 6 months. A Norway survey reported about 80% declined after graded exercise therapy; structured moderate activity over 12 to 26 weeks reduced fatigue compared with conventional/passive therapies; after a maximal exercise test, pain, fatigue, and confusion changed, with Clostridium in blood at 15 min and Bacilli increased at 48 h. Authors state current research lacks comprehensive insights and studies often produce conflicting findings, with varied diagnostic criteria and small samples.
- Treating chronic fatigue syndrome - a study into the scientific evidence for pharmacological treatments.2011 · review
Summary
The paper reports a questionnaire survey of 94 CFS patients from Queensland and New South Wales, recruited through support groups and newspaper and email advertisements, plus a search for randomised controlled trials. Patients filled out a questionnaire on current medicines and supplements; no treatment was given by the authors, and the survey had no comparison group. The 94 patients used 474 different medicines and supplements. Commonly used were antidepressants (41%), sedatives (27%), B vitamins (47%), magnesium (24%) and co-enzyme Q10 (7%). The search identified 20 RCTs. Findings included no difference for fluoxetine on fatigue or SF-36, no difference between treatment and placebo on individual questionnaires, and no effect for several agents including phenelzine, moclobemide, valaciclovir, terfenadine, melatonin, ginseng, bovine liver extract and a polynutrient supplement. One hydrocortisone trial reported 87% rated themselves improved versus 17% on placebo (p<0.001); another reported 53% vs. 29% (p=0.04) improvement in wellness score. Harm notes included diarrhoea with high-dose oral magnesium, long-term adrenal gland suppression with adrenal hormones, addiction and loss of effectiveness with benzodiazepines and opiates, and hormonal/lipid changes with DHEA. No worsening or stopping was reported. The authors state limitations.
- Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?2010 · review
Summary
This review examined pharmacotherapy for chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME), focusing on non-antidepressant controlled drug trials published between 1988 and August 2009. It did not report one overall number of enrolled patients. In the methylphenidate trial (60 CFS patients), clinically significant improvement on the Checklist of Individual Strength concentration subscale occurred in 13 patients taking methylphenidate (22%) versus three taking placebo (5%; p = 0.01); the number needed to treat was 6 [95% CI: 4.6 to 8.6]. A clinically significant fatigue response occurred in 10 patients (17%) with methylphenidate versus no patients with placebo; the number needed to treat was 6 (95% CI: 3.8 to 14.4). No effect was observed on bodily pain, mental health, depression and anxiety, and no severe side effects were reported. Other reviewed trials reported no significant effect for aciclovir, no beneficial effects for ganciclovir, no differences versus placebo for oral terfenadine (n = 30), and no effect for immunoglobulin in a large RCT (n = 99). In a doxycycline RCT (n = 491), there were no statistically significant differences versus placebo; the doxycycline group had a higher incidence of nausea and photosensitivity. Two participants in a magnesium RCT (n = 34) dropped out, one because of generalized rash.